You can buy or sell TCRR and other stocks, options, ETFs, and crypto commission-free!
TCR2 Therapeutics Inc. Common Stock, also called TCR2 Therapeutics, is an immunotherapy company, which develops biological drugs and engineering t-cells for cancer therapy. Read More The firm offers cancer therapy, t-cell biology, immunology and molecular biology. It also engages in the research and collaboration with academic laboratories and industry partners in the field of t-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle in May 2015 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
— per share
Expected May 11, Pre-Market